“With New Product Growth and U.S. Market Expansion”... Celltrion Price Target Raised
- Input
- 2026-11-17 08:47:25
- Updated
- 2026-11-17 08:47:25

[Financial News] Daol Investment & Securities forecast that Celltrion would continue to grow its earnings next year, driven by rising sales of high-margin new products and accelerated expansion into the U.S. market. It maintained its “Buy” rating and raised its target price from KRW 290,000 to KRW 310,000.
Lee Ji-su, an analyst at Daol Investment & Securities, said on the 17th, “Rising sales of high-margin new products such as OMLYCLO and Steqeyma, along with an improved product mix, will drive earnings growth,” and analyzed that “the growth contribution from new products is expected to add to stable sales of existing biosimilars.”
Daol Investment & Securities estimated that Celltrion’s 2027 consolidated revenue would rise 18.7% year on year to KRW 6.9016 trillion, while operating profit would increase 29.6% to KRW 2.4674 trillion. It forecast that the operating margin would climb from this year’s projected 32.8% to 35.8%.
Sales of new products are expected to gain momentum in the U.S. market in particular. OMLYCLO, launched in the U.S. last month, and Eydenzelt, scheduled for launch at the end of the year, are seen as growth drivers. The analyst forecast that OMLYCLO sales would rise 55.1% from this year to KRW 729.9 billion next year, while Steqeyma sales would also grow 72.6% to KRW 357.5 billion.
In the medium to long term, the expiration of patents on global blockbuster drugs also presents an opportunity. The analyst forecast that “follow-on biosimilars for drugs such as Keytruda and Cosentyx are under development,” and that “the U.S. Food and Drug Administration (FDA)’s streamlining of development and approval procedures will also be a favorable factor.”
[email protected] Im Sang-hyeok Reporter